US20060134039A1 - Nail restructuring compositions for topical application - Google Patents

Nail restructuring compositions for topical application Download PDF

Info

Publication number
US20060134039A1
US20060134039A1 US10/559,794 US55979405A US2006134039A1 US 20060134039 A1 US20060134039 A1 US 20060134039A1 US 55979405 A US55979405 A US 55979405A US 2006134039 A1 US2006134039 A1 US 2006134039A1
Authority
US
United States
Prior art keywords
component
extract
nail
agents
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/559,794
Other languages
English (en)
Inventor
Federico Mailland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polichem SA
Original Assignee
Polichem SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33395922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060134039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polichem SA filed Critical Polichem SA
Publication of US20060134039A1 publication Critical patent/US20060134039A1/en
Assigned to POLICHEM SA reassignment POLICHEM SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAILLAND, FEDERICO
Priority to US12/659,140 priority Critical patent/US8318214B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9741—Pteridophyta [ferns]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A61Q3/02—Nail coatings

Definitions

  • the present invention relates to a composition comprising at least a herb from the genus Equisetum and one film forming agent and its use as a nail topical formulation.
  • the present invention is further directed to the use of a water soluble film forming agent as an additive in a nail topical formulation.
  • the strength and physical character of the nail plate is attributable to both its constituents and design.
  • the features of design worthy of note are the double curvature, in transverse and longitudinal axes, and the flexibility of the ventral plate compared to the dorsal aspect.
  • the first one provides rigidity, whereas the latter allows moderate flexion deformity and slightly less extension.
  • the most proximal component of the matrix provides the corneocytes of the dorsal nail surface. These usually provide a shiny surface. When the matrix is altered by disease or the nail surface Is subject to trauma, this shine is lost.
  • Onychoschizia and ungual brittleness is a widespread condition that affects mainly housewives, workmen and workwomen, dressmakers, nurses, but also employees.
  • Longitudinal grooves represent long-lasting conditions that can occur physiologically as shallow and delicate furrows, usually parallel and separated by low, projecting ridges. They become more prominent with age and in certain pathological conditions.
  • Longitudinal ridges are small rectilinear projections that extend from the proximal nail fold until the free edge of the nail, or may stop shorter. Oblique lines (chevron lines) are more common in children than in adults and their significance is still debatable.
  • Transverse lines in form of sulci limited proximally by slightly elevated ridges and affecting the surface of all nails at the corresponding level, have been described as retrospective indicators of a number of pathological status. They reflect a temporary reduction in nail matrix activity.
  • Lamellar splitting is a condition found in 27-35% of normal adult women. The distal portion of the nail splits horizontally in this condition. The nail is formed in layers analogous to the formation of scales in the skin: the thin lamellae then break off. Exogenous factors contribute to the defect it is common in people who carry out a great deal of housework, whose nails are repeatedly soaked in water and then dried.
  • Healthy looking nails should be smooth, curved, void of any spotting, and should not have any hollows or ridges. Nails in bad conditions can be very harmful for the personal image, if neglected can cause chronic infections, associated to long-lasting embarassment and pain. Noteworthy, they may be considered a social problem and/or a professional illness.
  • the following can be included: breaking, splitting, fracturing, brittleness, white spots or ridges, poor nail growth, color or shape changes.
  • Mineral oil has no effect on flexibility, although it can act to maintain some of the flexibility imbued by water.
  • This principle is applied in the treatment of onychoschizia, where repeated hydration and drying of the nail plate results in splitting at the free edge. Splitting can be partially overcome by applications of emollients after soaking the nails in water.
  • the use of a nail varnish, normally a water insoluble polyvinyl resin film, can also decrease water loss: the disadvantage of that procedure is that the removal of the nail varnish by an organic solvent can further damage the nail structure by increasing brittleness and splitting.
  • the object of the present invention is to provide a novel nail topical formulation comprising
  • the present invention is directed to the use of said composition as a nail topical formulation, such as varnish, cream, gel, lotion or foam.
  • the composition in accordance to the present invention comprises as a component a) at least one herb extract from the genus Equisetum.
  • the herb extract may be selected from any known species belonging to the genus Equisetum, moreover it may be a dry extract, or an alcoholic extract, or an hydro alcoholic extract, or a glycolic extract. Examples include:
  • the herb extract is preferably selected from Equisetum arvense.
  • the herb extract may be used alone or may be a mixture of different extracts.
  • the preferred amount of component a) in the composition is in the range of 0.1 to 15 wt. %, more preferably 0.3 to 15 wt. %, most preferably 0.5 to 10 wt. % by weight of the total composition.
  • the composition of the present invention also comprises as a component b) at least one film forming agent, preferably a water soluble film forming agent.
  • the water soluble film forming agent may be selected from any water soluble film forming agent known in the art. Film forming agents are by definition (see e.g. DIN 55945 (19/1988)) components of a binder which are essential for forming a film, i.e. a thin layer or cover.
  • water soluble means in this context that the film forming agent is fully compatible with water so that at 20° C. one part of the film forming agent is soluble in 100 parts or less, preferably 50 parts or less, more preferably 30 parts or less, most preferably 10 parts or less of water.
  • the use of a wide variety of agents is possible, ensuring, thus, an easy application of the drug and simplifying also the storage of the formulation.
  • the film forming agent may be used with a wide variety of solvents, the formulation can be chosen in a way that the nail topical formulation composition in accordance with the present invention does not burn nor cause irritation and is easily removable without the use of organic solvents.
  • the water soluble film forming agent used in the composition according to the present invention provides a non-glossy, non-sticky and very plastic film which possesses a matte and natural look favored by both women and men.
  • macromolecular compounds of synthetic or natural origin can be used, which are water soluble or have been derivatized by functional groups in order to impart water solubility.
  • water soluble derivatives of naturally occurring polymers or derivatives of naturally occurring polymers are employed. It is particularly preferred to use water soluble derivatives of chitosan, the latter being the deacylation product of chitin and being itself water insoluble.
  • Chitin is a natural substance constituting, for example, the carapace of crustaceans and many insects.
  • hydroxyalkyl chitosans and carboxyalkyl chitosans.
  • Hydroxyalkyl chitosans include chitosans which are derivatized with C 1-6 alkyl groups possessing 1 to 3 hydroxy groups.
  • hydroxypropyl chitosan can be mentioned.
  • Carboxyalkyl chitosans include chitosans which are derivatized with C 1-6 alkyl groups possessing 1 to 3 hydroxy groups.
  • carboxymethyl chitosan can be mentioned.
  • the water soluble film forming agent (component b)) can be used in an amount as long as the formation of a film of the claimed composition can be provided.
  • the amount of the component b) is in the range of 0.1 to 10 wt. %, more preferably 0.3 to 8 wt. %, most preferably 0.5 to 5 wt. % by weight of the total composition.
  • composition in accordance with the present invention further comprises usually as a component c) at least one physiologically acceptable carrier, preferably a solvent.
  • the solvents typically a water based solvent in order to avoid a frequent and repeated exposure of the nails and the adjacent skin to aggressive organic solvents.
  • the physiologically acceptable solvent includes water and mixtures of water with co-solvents.
  • the co-solvent which can be used in combination with water in the composition in accordance with the present invention is not particularly critical but is selected from the usual physiologically safe organic solvents known in the art.
  • the co-solvent is a hydrophilic solvent and it is preferably selected from alcohols.
  • Suitable alcohols are branched or linear alcohols having 1 to 3 hydroxy groups and 2 to 6 carbon atoms whereby the hydroxy groups may be partially converted to ethers.
  • Particularly suitable alcohols are ethanol, 1-propanol, 2-propanol (isopropanol).
  • Particularly suitable are ethanol or isopropanol.
  • the total amount of co-solvent used in combination with water present in the composition in accordance with the present invention is sufficient volatile to provide acceptable drying times of the nail topical formulation. Usual drying times, i.e. the time taken to be dry by touch, are less than about five minutes, preferably less than about two minutes.
  • the solvent systems used in accordance with the present invention should not only provide uniform evaporation rates and good stability but also enable good flow viscosity characteristics in order to ease the application of the nail topical formulation.
  • the at least one physiologically acceptable solvent (component c)) is usually employed in an amount suitable in order to impart the above noted properties. It is preferred that the component c) is present in the composition in accordance with the present invention in an amount of 40 to 99.8 wt. %, more preferably 60 to 99 wt. %, most preferably 80 to 95 wt. % by weight of the total composition.
  • the water content in component c) is typically 15 to 70 wt. %, preferably 30 to 65 wt. % by weight of component c) in order to impart the desired properties. Consequently, the co-solvent used in combination with water is typically present in an amount of 30 to 85 wt. %, preferably 35 to 70 wt. % by weight of component c) in order to impart the above noted properties.
  • composition according to the present invention may further contain other active agents besides the Equisetum herb extract, e.g. sulfur donors, antimycotic agents, antibiotic agents, anti-inflammatory agents, antiseptic agents and/or local anaesthetic agents.
  • active agents e.g. sulfur donors, antimycotic agents, antibiotic agents, anti-inflammatory agents, antiseptic agents and/or local anaesthetic agents.
  • Sulfur donors may interact with the formation and/or the reconstruction process of the nail keratin.
  • sulfur donors examples include sulphated amino acids and derivatives, 1-methionine, 1-cysteine, 1-cystine, taurine, 4-thiazolidinecarboxylic acid, methylsulphonylmethane.
  • agents may be used in the respective amounts customary in the art. They are usually employed in an amount from 0.1 to 20 wt. %, preferably from 0.2 to 10 wt. %.
  • antimycotic agents examples include imidazole derivatives and their salts; triazole derivatives and their salts; pyridone derivatives like ciclopirox, octopirox and their salts; polyene derivatives and their salts; allylamine derivatives like terbinafine and their salts; morpholine derivatives like amorolfine and their salts; bromsalan derivatives and their salts; nystatin and related compounds; griseofulvin and related compounds; chlorphenesin and related compounds; clodantoin and related compounds; undecylenic acid and its salts and the antimycotic agents disclosed in WO 02/07863A1.
  • agents may be used in the respective amounts customary in the art. They are usually employed in an amount from 0.1 to 15 wt. %.
  • antibiotic agents which may be listed in the composition in accordance with the present invention include aminoglycosides and their salts; antimycobacterials and their salts; cephalosporins and related beta lactams and their salts; chloramphenicol and related compounds; glycopeptides and their salts; fusidane derivatives and their salts; lincosamides and their salts; macrolides and their salts; mupirocin and related compounds; nitrofuran derivatives and their salts; oxazolidinone derivatives and their salts; penicillins and their salts; phosphonic acid derivatives and their salts; polimixins and their salts; polypeptide antibacterials and related compounds; quinolones and their salts; sulfonamides and diaminopyrimidines and their salts; tetracyclines and their salts.
  • antibiotic agents may be used in the respective amounts customary in the art.
  • the antibiotic agents are usually employed in an amount from 0.1 to 10 wt. %.
  • the anti-inflammatory agent which may be used in the composition in accordance with the present invention include steroidal and nonsteroidal anti-inflammatory agents.
  • steroidal anti-inflammatory agents include 21-acetoxypregnenolone, alclometasone or its dipropionate salt, algestone, amcinonide, beclomethasone or its dipropionate salt, betamethasone and salts thereof, including, for example, betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, betamethasone sodium phosphate and acetate, and betamethasone valerate; clobetasol or its propionate salt, clocortolone pivalate, hydrocortisone and salts thereof, including, for example, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone phosphate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone tebutate and hydrocortisone valerate; cortisone acetate, budesonide, desonide, desoxi
  • acetate, sodium succinate mometasone furoate, paramethasone acetate, prednisolone and salts thereof, e.g., acetate, diethylaminoacetate, sodium phosphate, sodium succinate, tebutate, trimethylacetate; prednisone, triamcinolone and derivates thereof, e.g. acetonide, benetonide, diacetate, hexacetonide.
  • nonsteroidal antiinflammatory agents include acetylsalicylic acid, buthylpyrazolidines and their salts; acetic acid derivatives and their salts; oxicam derivatives and their salts; propionic acid derivatives and their salts; phenamates and their salts; coxibs and their salts; nimesulide and related compounds.
  • antiinflammatory agents may be used in the respective amounts customary in the art.
  • the anti-inflammatory agents are usually employed in an amount from 0.1 to 5 wt. %.
  • antiseptic agents which may be used in the composition in accordance with the present invention include benzalkoniumchlorid, benzethoniumchlorid, cetrimoniumbromid, chlorhexidin, dequaliniumchlorid, triclocarban, triclosan, salicvlic acid, benzoic acid sorbic acid and their salts, p-hydroxybenzoic acid and its esters.
  • antiseptic agents may be used in the respective amounts customary in the art.
  • the antiseptic agents are usually employed in an amount from 0.01 to 5 wt. %.
  • examples of local anaesthetic agents which may be used in the composition in accordance with the present invention include benzocaine, butamben and its picrate, piperocaine hydrochloride, oxybuprocaine hydrochloride, tetracaine hydrochloride, lidocaine hydrochloride, cinchocaine hydrochloride, oxetacaine, propiocaine hydrochloride, bupivacaine hydrochloride, mepivacaine hydrochloride, dyclonine hydrochloride, fomocaine hydrochloride, quinisocaine hydrochloride, polydocanol and benzyl alcohol.
  • local anaesthetic agents may be used in the respective amounts customary in the art.
  • the local anaesthetic agents are usually employed in an amount from 0.3 to 10 wt. %.
  • the composition in accordance with the present invention may contain other conventional additives customarily present in cosmetic or medicinal nail lacquers, in particular penetration enhancers.
  • Penetration enhancers include any compound known in the art which can enhance the penetration of the pharmacologically active compound through the skin or through the nail. In other words, the penetration enhancer improves the deep diffusion of the drug.
  • Suitable penetration enhancers include salycilic acid, urea, monothioglycerol, N-acethylcysteine, ethyl acetate, d-methyl sulphoxide (DMSO), dimethylacetamide and the penetration enhancers disclosed in WO 99/39680.
  • the penetration enhancers may be used in an amount of 0 to 10 wt. %, preferably 0.1 to 8 wt. %, most preferably 1 to 5 wt. % by weight of the total composition.
  • Other conventional additives customarily present in cosmetic or medicinal nail formulatlons may include sedimentation retarders, chelating agents, antioxidants, silicates, aroma substances, wetting agents, lanolin derivates, light stabilizers and antibacterial substances.
  • composition in accordance to the present invention may be prepared according to typical procedures normally employed in the formulation field for liquid preparations, like solutions, nail varnish, lotion or foam, or for semi-solid preparations, like cream or gel.
  • the at least one herb extract from the genus Equisetum and the at least one water soluble film forming agent may be brought into contact with a solvent or a mixture of solvents and other liquid components either simultaneously or separately by normal mixing techniques. No particular order of addition of the respective ingredients is required. It is preferred to provide stirring in order to ensure complete dissolution of the ingredients. If any of the ingredients is in the solid form, it is particularly preferred to add such an ingredient gradually to the liquid components in order to prevent clumping.
  • the at least one herb extract from the genus Equisetum and the at least one water soluble film forming agent may be mixed with suitable excipients, like solvents, emulsifyiers, surfactants and/or stiffening agents, either simultaneously or separately by normal mixing techniques. It is preferred to provide stirring under heating and surcharge the solvent in order to avoid losses of evaporation.
  • composition in accordance with the present invention is applied as a film or as a thin layer on the nail surface in order to prevent and/or treat specific alterations of the ungual structure, like reduced strength, onychoschizia and ungual brittleness.
  • the composition will be applied repeatedly over a period of several weeks or months, depending on the ungual status.
  • the applied composition will contain sufficient active principle to be diffused into the nail so that the application should be repeated only once or twice per day in order to ensure its effectiveness.
  • the preferred film forming agents of the present invention show a surprising potentiation effect when employed with Equisetum herb extracts. This effect is particularly pronounced with hydroxyalkyl chitosans and carboxyalkyl chitosans.
  • composition of the present invention and its use as a nail restructuring and hardening formulation is illustrated, but not limited to, the following examples. All amounts in % are wt. %
  • a nail lacquer formulation having the following composition by weight is prepared: 1. purified water 52.5% 2. ethanol 40.0% 3. Equisetum glycolic extract 5.0% 4. hydroxypropyl chitosan (HPCH) 1.0% 5. L-methionine 1.0% 6. diethyleneglycol monomethylether 0.5%
  • the formulation was prepared by using a suitable closed vessel provided with a stirrer. To this vessel were added ethanol, deionized water and diethyleneglycol-monomethylether to form a mixture. Thereafter, after dissolution thereof, Equisetum arvense glycolic extract and L-methionine were added. Finally, hydroxypropyl chitosan was added and the resulting mixture was stirred for 24 hours or until dissolution.
  • the obtained nail lacquer composition had a clear and homogeneous appearance and a yellowish color even after prolonged storage. Moreover, the lacquer was able to form a matte, non-sticky and plastic film which could strongly adhere to the nails. When applied, the moisture and air permeable lacquer did not burn or cause irritation on the adjacent skin or the periungual bed.
  • a nail lacquer formulation having the following composition by weight is prepared: 1. purified water 50.5% 2. ethanol 40.0% 3. Equisetum glycolic extract 4.0% 4. aroma cherry 3.0% 5. hydroxypropyl chitosan (HPCH) 1.0% 6. 4-thiazolidinecarboxilic acid 1.0% 7. cetostearyl alcohol 0.5%
  • Example 1 The formulation was prepared as shown in the Example 1 and the resulting nail lacquer exhibited the same properties as mentioned in Example 1.
  • a nail lacquer formulation having the following composition by weight is prepared: 1. purified water 51.0% 2. ethanol 40.0% 3. Equisetum glycolic extract 5.0% 4. aroma Tropical 3.0% 5. hydroxypropyl chitosan (HPCH) 0.5% 6. ethyl acetate 0.5%
  • Example 1 The formulation was prepared as shown in the Example 1 and the resulting nail lacquer exhibited the same properties as mentioned in Example 1.
  • a nail lacquer formulation having the following composition by weight is prepared: 1. purified water 52.5% 2. ethanol 40.0% 3. Equisetum glycolic extract 5.0% 4. hydroxypropyl chitosan (HPCH) 1.0% 5. methylsulphonylmethane 1.0% 6. diethyleneglycol monomethylether 0.5%
  • Example 1 The formulation was prepared as shown in the Example 1 and the resulting nail lacquer exhibited the same properties as mentioned in Example 1.
  • a nail lacquer formulation having the following composition by weight is prepared: 1. purified water 49.0% 2. ethanol 40.0% 3. Equisetum glycolic extract 5.0% 4. aroma cherry 3.0% 5. carboxymethyl chitosan (HPCH) 1.0% 6. methylsulphonylmethane 1.0% 7. cetostearyl alcohol 0.5% 8. ethylacetate 0.5%
  • Example 1 The formulation was prepared as shown in the Example 1 and the resulting nail lacquer exhibited the same properties as mentioned in Example 1.
  • a nail lacquer formulation having the following composition by weight is prepared: 1. purified water 49.0% 2. ethanol 40.0% 3. Equisetum glycolic extract 5.0% 4. aroma cherry 3.0% 5. hydroxypropyl chitosan (HPCH) 1.0% 6. L-methionine 1.0% 7. diethyleneglycol monomethylether 0.5%
  • Example 1 The formulation was prepared as shown in the Example 1 and the resulting nail lacquer exhibited the same properties as mentioned in Example 1.
  • a cream formulation having the following composition by weight is prepared: 1. purified water 61.5% 2. cetyl alcohol 5.5% 3. stearyl alcohol 5.5% 4. 2-octyldodecanol 5.5% 5. Equisetum glycolic extract 5.0% 6. coconut fatty acid diethanolamide 4.0% 7. vaseline album 3.5% 8. polysorbate 60 3.5% 9. light liquid paraffin 2.5% 10. sorbitanmonostearate 1.5% 11. hydroxypropyl chitosan (HPCH) 1.0% 12. benzyl alcohol 1.0%
  • the formulation was prepared by using a suitable stainless steel tank, provided with a thermosetting system and stirrer. To this tank were added cetyl alcohol, stearyl alcohol, 2-octyldodecanol, coconut fatty acid diethanolamide, vaseline album, polysorbate 60, light liquid paraffin, sorbitanionostearate and benzyl alcohol. The mixture has been heated and maintained at 70-75° C. under stirring conditions. Thereafter, Equisetum arvense glycolic extract and hydroxypropyl chitosan were added under stirring. Finally, water was added at 75-80° C. and stirred for 5 minutes. The water was surcharged by 10% to avoid losses of evaporation. Then the mixture was cooled at 28-30° C. and unloaded in a stainless tank.
  • the obtained cream composition had a clear and homogeneous appearance and a yellowish color even after prolonged storage.
  • the cream was able to form a plastic layer which could strongly adhere to the nails, did not burn or cause irritation on the adjacent skin or the periungual bed.
  • a foam formulation having the following composition by weight is prepared: 1. propylene glycol 60.3% 2. purified water 30.0% 3. Equisetum glycolic extract 5.0% 4. coconut fatty acid diethanolamide 3.5% 5. hydroxypropyl chitosan (HPCH) 1.0% 6. trimethylcetylammonium P-toluene sulfonate 0.2%
  • the formulation was prepared by using a suitable stainless steel tank, provided with a stirrer. Equisetum extract was dissolved in propylene glycol, then an aqueous solution containing hydroxypropyl chitosan, trimethylacetyl ammonium p-toluenesulfonate and coconut fatty acids diethanolamide were added. The mixture has been maintained at 25-30° C. under stirring conditions.
  • the above liquid once put into the vessel equipped with the appropriate device, supplied a soft and persisting foam, which could be spread on the nails providing a matte film that strongly adhered to the nail surface.
  • a gaseous propellant at ordinary pressure or a liquid one at high pressure, such as isobutane in a normal pressurized bottle.
  • a lotion formulation having the following composition by weight is prepared: 1. polyethylene glycol 400 93.89% 2. Equisetum glycolic extract 5.00% 3. hydroxypropyl chitosan (HPCH) 1.00% 4. lactic acid 0.10% 5. buthylhydroxyanisole 0.01%
  • the formulation was prepared by using a suitable stainless steel dissolution tank, provided with a stirrer and a heating-cooling jacket.
  • the polyethylene glycol has been heated up to 32-35° C. by forcing vapor through the heating jacket of the dissolution tank. Then, while stirring, the ingredients have been added and dissolved. Upon dissolution, the mixture has been stirred for 3 hours to homogenize.
  • the above lotion once put on the nails, provided a matte film that strongly adhered to the nail surface.
  • the product has been applied monolaterally once daily, preferably on the night, on all the nails of one hand, on the entire nail surface, for 28 consecutive days.
  • the hand to be treated was randomly assigned, the other hand served as the untreated control.
  • the efficacy parameters according to the protocol have been recorded at baseline and after 14 and 28 days. It included a clinical assessment of the treated and untreated nails and the casts of the thumb nails of both hands, made by silicon resin.
  • the casts have been analyzed by computerized optical prophylometry according to a validated method.
  • the longitudinal ridges have been measured as average roughness score on the nail casts (Ra).
  • the Ra score was 10.96 ⁇ SD 2.58 at baseline, 9.46 ⁇ 2.08 after 14 days and 8.99 ⁇ 1.72 after 28 days on the nails treated with the composition according to Example 1. In mean, there was a decrease by 14% at the intermediate evaluation time and a decrease by 18% at the end of application.
  • dystrophy, onycholysis, onychoschizia and ungual brittleness have been measured by a 4-point semi quantitative scale. While there was no change in dystrophy or onycholysis in either group, a definite improvement of both onychoschizia and ungual brittleness was recorded in treated nails, significantly better (p ⁇ 0.001) for both parameters than the results recorded in untreated nails.
  • the product has been applied on the entire nail surfaces of both hands once daily, preferably on the night, for 4 consecutive weeks.
  • Table 2 Subject global impression after 4 weeks of treatment with the composition according to the Example 1 (group 1), a composition like that indicated in Example 1, without hydroxypropyl chitosan (group 2), and a composition like that indicated in Example 1, without Equisetum herb extract (group 3): p ⁇ 0.001 between group 1 and group 2; p ⁇ 0.001 between group 1 and group 3. worsened no change improvement revovery Group n° subjects n° subjects n° subjects n° subjects 1 0 0 12 8 2 1 8 11 0 3 0 14 6 0

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US10/559,794 2003-06-23 2004-06-15 Nail restructuring compositions for topical application Abandoned US20060134039A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/659,140 US8318214B2 (en) 2003-06-23 2010-02-26 Method for treating onychoschizia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20030076934 EP1491202A1 (de) 2003-06-23 2003-06-23 Nagel-restrukturierende Zusammensetzungen zur topischen Applikation
EP03076934.3 2003-06-23
PCT/EP2004/006549 WO2004112814A1 (en) 2003-06-23 2004-06-15 Nail restructuring compositions for topical application

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/659,140 Continuation-In-Part US8318214B2 (en) 2003-06-23 2010-02-26 Method for treating onychoschizia

Publications (1)

Publication Number Publication Date
US20060134039A1 true US20060134039A1 (en) 2006-06-22

Family

ID=33395922

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/559,794 Abandoned US20060134039A1 (en) 2003-06-23 2004-06-15 Nail restructuring compositions for topical application
US12/659,140 Active 2025-06-07 US8318214B2 (en) 2003-06-23 2010-02-26 Method for treating onychoschizia

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/659,140 Active 2025-06-07 US8318214B2 (en) 2003-06-23 2010-02-26 Method for treating onychoschizia

Country Status (22)

Country Link
US (2) US20060134039A1 (de)
EP (2) EP1491202A1 (de)
JP (1) JP5037121B2 (de)
KR (2) KR101140272B1 (de)
CN (1) CN100430044C (de)
AT (1) ATE369870T1 (de)
BR (1) BRPI0411705B1 (de)
CA (1) CA2528313C (de)
CY (1) CY1106949T1 (de)
DE (1) DE602004008272T2 (de)
DK (1) DK1635852T3 (de)
ES (1) ES2289527T3 (de)
HK (1) HK1092689A1 (de)
HR (1) HRP20070431T3 (de)
IL (1) IL172180A (de)
ME (2) MEP23108A (de)
MX (1) MXPA05013820A (de)
PT (1) PT1635852E (de)
RS (1) RS51879B (de)
RU (1) RU2358748C2 (de)
SI (1) SI1635852T1 (de)
WO (1) WO2004112814A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127342A1 (en) * 2004-12-09 2006-06-15 Georgia Levis Taurine-based compositions, therapeutic methods, and assays
US20100104670A1 (en) * 2007-02-14 2010-04-29 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958638A1 (de) * 2007-02-14 2008-08-20 Polichem S.A. Verwendung von Chitosanen zum Erhöhen der Nagelwachstumsrate
EP1958613A1 (de) * 2007-02-15 2008-08-20 Polichem S.A. Dermale filmbildende flüssige Formulierungen zur Wirkstofffreisetzung auf der Haut
IT1390844B1 (it) * 2008-07-29 2011-10-19 Trasdeco Int S R L Composizione cosmetica per unghie e relativo metodo di applicazione
EP2153836A1 (de) * 2008-08-04 2010-02-17 Polichem S.A. Filmbildende flüssige Formulierungen zur Wirkstofffreisetzung im Haar und auf der Kopfhaut
EP2116237A1 (de) 2008-08-05 2009-11-11 Polichem SA Zusammensetzungen enthaltend Chitosan und Dicarboxysäure zur Behandlung von Rosacea
TR201103770A1 (tr) * 2011-04-19 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Nimesulid ve metilsülfonilmetanin topikalfarmasötik bileşimleri.
US8697753B1 (en) 2013-02-07 2014-04-15 Polichem Sa Method of treating onychomycosis
EP2845597A1 (de) * 2013-09-10 2015-03-11 Polichem S.A. Hydroxypropylchitosan zur Behandlung von Onychomykose
EP2952208A1 (de) * 2014-06-04 2015-12-09 Universidade de Santiago de Compostela Hydroalkoholisches System zur Nagelbehandlung
JP6570316B2 (ja) * 2015-05-25 2019-09-04 ロート製薬株式会社 爪用組成物
KR102485403B1 (ko) 2020-08-31 2023-01-17 주식회사 비앤에이치웍스 손발톱 강화용 조성물
KR102597564B1 (ko) * 2023-03-03 2023-11-03 장병모 조갑 및 피부 백선의 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114324A1 (en) * 2001-12-14 2003-06-19 Rainer Lange Cleansing compositions and their use in feminine hygiene wipes
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610523B1 (fr) * 1987-02-06 1991-04-26 Synthelabo Extrait dose de silicium biogene, sa preparation et son application en therapeutique
US5133958A (en) * 1989-04-20 1992-07-28 Erwin Stuckler Agent for nail, skin and hair care
US5478579A (en) * 1991-02-06 1995-12-26 Biodyn Medical Research, Inc. Method for treatment of osteoporosis
FR2681782B1 (fr) * 1991-09-26 1993-12-17 Oreal Composition pour le traitement des ongles contenant un aminoacide soufre.
DE59406934D1 (de) * 1993-05-02 1998-10-22 Helmut Koeniger Neue verwendung von equisetum
FR2718637A1 (fr) * 1994-04-15 1995-10-20 Oreal Composition cosmétique à appliquer sur l'ongle.
RU2083224C1 (ru) 1994-09-30 1997-07-10 Сергей Федорович Подчайнов Противогрибковое средство для стоп
US6027402A (en) * 1996-11-18 2000-02-22 Sunfiles, Llc Cosmetic file/buffer with microencapsulated treatment substances
WO1998048768A1 (en) * 1997-05-01 1998-11-05 Medlogic Global Corporation Compositions for cosmetic applications
JPH11193217A (ja) * 1997-12-26 1999-07-21 Kao Corp ネイルトリートメント組成物
DE19826943C2 (de) 1998-06-17 2001-12-06 Daimler Chrysler Ag Tunnelverkleidung für ein Kraftfahrzeug
AU4984899A (en) 1998-07-14 2000-02-07 Adams Food Ltd. Nutritionally active composition for hardening fingernails
US6589571B2 (en) * 1998-08-13 2003-07-08 Helmut Koniger Method for combating summer eczema and malanders
RU2140264C1 (ru) 1998-09-24 1999-10-27 Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН Средство для наружного применения "полимед"
KR20010026947A (ko) * 1999-09-09 2001-04-06 이충삼 건강보조식품 제조방법
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
DE10035991A1 (de) * 2000-07-24 2002-02-14 Polichem Sa Nagellackzusammensetzung
JP2002179521A (ja) * 2000-12-13 2002-06-26 Ichimaru Pharcos Co Ltd 植物又は動物抽出物含有化粧料組成物
EP1275371A1 (de) * 2001-07-13 2003-01-15 Johnson and Johnson GmbH Trockene, eine Folie und zwei Phasen enthaltende, Produkte
FR2829696B1 (fr) * 2001-09-17 2004-02-27 Oreal Utilisation de l'acide pantetheine sulfonique et/ou de ses sels en tant qu'agent anti-radicalaire
CA2383296A1 (fr) * 2002-05-10 2003-11-10 Ginette Godbout Composition pour l'amelioration de la sante et de la structure des ongles, methode d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919076B1 (en) * 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US20030114324A1 (en) * 2001-12-14 2003-06-19 Rainer Lange Cleansing compositions and their use in feminine hygiene wipes

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127342A1 (en) * 2004-12-09 2006-06-15 Georgia Levis Taurine-based compositions, therapeutic methods, and assays
US20100104670A1 (en) * 2007-02-14 2010-04-29 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
KR101468479B1 (ko) * 2007-02-14 2014-12-05 폴리켐 에스.에이. 조갑 염증 질환의 치료를 위한 키토산의 용도
US8906881B2 (en) * 2007-02-14 2014-12-09 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases

Also Published As

Publication number Publication date
EP1491202A1 (de) 2004-12-29
RS51879B (sr) 2012-02-29
RU2358748C2 (ru) 2009-06-20
WO2004112814A1 (en) 2004-12-29
MXPA05013820A (es) 2006-06-27
JP2007507421A (ja) 2007-03-29
CA2528313C (en) 2013-02-19
ES2289527T3 (es) 2008-02-01
DK1635852T3 (da) 2007-12-10
ATE369870T1 (de) 2007-09-15
KR20120027554A (ko) 2012-03-21
KR101140272B1 (ko) 2012-04-26
DE602004008272D1 (de) 2007-09-27
EP1635852A1 (de) 2006-03-22
SI1635852T1 (sl) 2007-12-31
ME00190B (me) 2011-02-10
EP1635852B1 (de) 2007-08-15
HRP20070431T3 (en) 2007-11-30
CA2528313A1 (en) 2004-12-29
DE602004008272T2 (de) 2008-05-08
US8318214B2 (en) 2012-11-27
RS20050925A (en) 2007-09-21
RU2006101686A (ru) 2006-07-27
MEP23108A (en) 2010-10-10
BRPI0411705B1 (pt) 2018-04-03
PT1635852E (pt) 2007-10-11
CN100430044C (zh) 2008-11-05
IL172180A (en) 2010-12-30
CN1812763A (zh) 2006-08-02
CY1106949T1 (el) 2012-09-26
BRPI0411705A (pt) 2006-08-08
US20100215780A1 (en) 2010-08-26
HK1092689A1 (en) 2007-02-16
KR20060021350A (ko) 2006-03-07
JP5037121B2 (ja) 2012-09-26

Similar Documents

Publication Publication Date Title
US8318214B2 (en) Method for treating onychoschizia
KR100530263B1 (ko) 항진균성 네일 바니쉬 조성물
US9173827B2 (en) Use of chitosans to increase nail growth rate

Legal Events

Date Code Title Description
AS Assignment

Owner name: POLICHEM SA,LUXEMBOURG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAILLAND, FEDERICO;REEL/FRAME:023989/0247

Effective date: 20051017

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION